LY3502970

oral non-peptide GLP-1R GPCR partial agonist

in Ph. I for Type 2 diabetes, HV study complete

from cell-based screen and opt.

PNAS, Nov. 11, 2020

Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN

Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks